Avoidance of axillary lymph node dissection in breast cancer patients with metastatic sentinel node – a pilot study
Authors:
M. Černá 1; I. Zedníková 1; A. Ňaršanská 1; T. Svoboda 2; O. Hes 3; J. Záhlava 4; M. Hlaváčková 4
Authors‘ workplace:
Chirurgická klinika FN v Plzni, přednosta: prof. MUDr. V. Třeška, DrSc.
1; Onkologická a radioterapeutická klinika FN v Plzni, přednosta: prof. MUDr. J. Fínek, Ph. D.
2; Šiklův ústav patologie FN v Plzni, přednosta: prof. MUDr. M. Michal
3; Klinika zobrazovacích metod FN v Plzni, přednosta: prof. MUDr. B. Kreuzberg, CSc.
4
Published in:
Rozhl. Chir., 2015, roč. 94, č. 3, s. 117-125.
Category:
Original articles
Overview
Introduction:
Axillary lymph node dissection (ALND) is a standard procedure for locoregional control in metastatic sentinel lymph nodes (SN). A number of studies have provided evidence that avoiding ALND does not worsen the general prognosis.
Methods:
A group of 249 female patients with sentinel lymph node biopsy was analysed retrospectively for a 3-year period. The patients were divided into two groups – with non-metastatic SN and with metastatic SN. In the metastatic SN group, the patients were further divided into a group with ALND and a group without ALND, and additional lymph nodes (non-sentinel) in ALND and oncological treatment were evaluated. The goal was to find out whether ALND and oncological treatment affect the disease-free interval (DFI) and overall survival (OS) in the group of patients with metastatic SN and to compare the results with the control group. The histopathology and biology of the primary tumour, its size and the number of metastatic SN were subsequently evaluated as the factors that may be useful for predicting metastatic non-sentinel lymph node positivity.
Results:
There was a high risk of metastatic non-sentinel lymph nodes in the cases of metastatic SN (63%). Addition of ALND does not prolong either DFI or DFS without post-operative radiotherapy and systemic oncological treatment, both of which can provide a comparable length of DFI as well as DFS without ALND. Patients with metastatic SN with and without ALND had a DFI of 70 and 72 months, respectively, and a 5-year survival of 84% and 80%, respectively. Tumours over 2 cm, tumours with high proliferative activity and a high grade can be regarded as predictors of metastatic non-sentinel lymph nodes.
Conclusion:
In a small patient group it has been demonstrated that the avoidance of ALND in 1 or 2 metastatic SN, regardless of the prognostic factors, does not affect either DFI or DFS if adjuvant oncological treatment is administered. High-grade tumours, tumours with high proliferative activity and tumours larger than 2 cm carry a significantly higher risk of metastatic non-sentinel lymph nodes. Nowadays, the avoidance of ALND in metastatic SN is not a lege artis procedure; further large studies are needed to create scientific guidelines.
Key words:
metastatic sentinel lymph node – avoidance of axillary dissection – breast cancer
Sources
1. Vrána D, Gatěk J, Cwiertka K, et al. Další postupný ústup od axilární disekce u časného karcinomu prsu. Klin Onkol 2014;27:143−5.
2. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat 2011;129:675−89.
3. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003;138:52–6.
4. Kamath V, Giuliano R, Dauway E, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:688–92.
5. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946−53.
6. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010;17 Suppl 3:343−51.
7. Gatzemeier W, Mann GB. Which sentinel lymph-node positive breast cancer patient needs an axillary lymph-node dissection ACOSOG Z0011 results and beyond. Breast 2013;22:211−6.
8. EORTC study shows radiotherapy and surgery provide excellent regional control for breast cancer patients. Dostupný z WWW: http://www.eortc.org/news/eortc-study-shows-radiotherapy-and-surgery-provide-excellent-regional-control-breast-cancer-pat.
9. Galimberti V, Cole BF, Zurrida S, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297−305.
10. Krsička P, Coufal O, Zapletal O. Pozitivní sentinelová uzlina u karcinomu prsu – kdy a proč doplňovat axilární disekci? Rozhl Chir 2013;92:684−9.
11. Latosinsky S, Berrang TS, Cutter CS, et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 2012;55:66−9.
12. Kotoč J, Kotočová K, Gatěk J, et al. Mikrometastáza v sentinelové uzlině – nutnost disekce axilárních uzlin? Prakt Lék 2009;89:587−90.
13. Joseph KA, El-Tamer M, Komenaka I, et al. Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis. Arch Surg 2004;139:648−51.
14. Abreu EB, Martinez P, Betancourt L, et al. Treatment plan for breast cancer with sentinel node metastasis. Ecancermedicalscience 2014;8:383.
15. Wong SL, Edwards MJ, Chao C, et al. Predicting the status of the nonsentinel axillary nodes. Arch Surg 2001;136:563−8.
16. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need komplete axillary node dissection? Ann Surg 1999;229:536–41.
17. Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastasis in axillary sentinel lymph nodes for patiens with breast carcinoma. Cancer 2001;92:1378−84.
18. Tjan-Heijnen V, Pepels M, Boer M, et al. Impact of omission of completion axillaries lymph node dissection or axillaries radiotherapy in breast cancer patients with micro metastasis or isolated tumor cells in the sentinel lymph node: results from the MIRROR study. J Clin Oncol 2009;27:18.
19. Rutledge H, Davis J, Chiu R, et al. Sentinel node micrometastasis in breast carcinoma may not be an indication for komplete axillary dissection. Mod Pathol 2005;18:762−8.
20. Fournier K, Schiller A, Perry RR, et al. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 2004;239:859−65.
21. Rahusen FD, Torrenga H, van Diest PJ, et al. Predictive factors for metastatic involvement of nonsentinel nodes in patiens with breast cancer. Arch Surg 2001;136:1059−63.
22. van Deurzen CH, van Hillegersberg R, Hobbelink MG, et al. Predictive value of tumor load in breast cancer sentinel lymf nodes for second echelon lymph node metastases. Cell Oncol 2007;29:497−505.
23. Menes TS, Tartter PI, Mizrachi H, et al. Breast cancer patients with pN0(iţ) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg 2005;200:323−7.
24. Boler DE, Uras C, Ince U, et al. Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases. Breast 2012;21:518−23.
25. Pernas S, Gil M, Benítez A, et al. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence. Ann Surg Oncol 2010;17:772–7.
26. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005;241:152–8.
27. Ozmen V, Karanlik H, Cabioglu N, et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 2006;95:1−6.
28. Dengel LT, Van Zee KJ, King TA, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol 2014;21:22−7.
29. Turner RR, Ku Chu, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000;89:574−81.
30. Harlow SP, Weaver DL. Sentinel lymph node dissection for breast cancer: Indications and outcomes. Dostupné z WWW: http://www.uptodate.com/contents/sentinel-lymph-node-dissection-for-breast-cancer-indications-and-outco
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2015 Issue 3
Most read in this issue
- Low anterior resection syndrome
- Surgical repair of recurrent pectus excavatum in adults and adolescents
- Delayed liver hematoma development following deceleration injury
- Avoidance of axillary lymph node dissection in breast cancer patients with metastatic sentinel node – a pilot study